Humacyte, Inc. (HUMA)Healthcare | Biotechnology | Durham, United States | NasdaqGS
0.71 USD
+0.03
(3.891%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.73 +0.02 (2.788%) ⇧ (April 17, 2026, 7:53 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:24 p.m. EDT
Avoid completely. Humacyte is a value trap with a deteriorating fundamental profile: negative earnings, massive cash burn ($105M operating loss), and a shrinking market cap driven by failed launch concerns (evidenced by analyst downgrades). Despite the 'Buy' recommendation and high analyst count, the price targets imply a precarious margin where market recovery is expected to offset operational failure. The 14-day price action shows range-bound weakness at sub-$1 levels, and the 45-day prediction model forecasts -11.4% returns with statistical instability (Jarque-Bera p-value of 0.144 indicating non-normal distribution risks). The technicals are bleeding (Price -24.5% beneath 50-day avg, -50% beneath 200-day avg). There is no near-term catalyst to reset the narrative. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.183160 |
| AutoARIMA | 0.204406 |
| AutoETS | 0.204423 |
| MSTL | 0.205334 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 10.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.144 |
| Excess Kurtosis | -1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2101.833 |
| Revenue per Share | 0.013 |
| Market Cap | 157,677,968 |
| Forward P/E | -3.87 |
| Beta | 2.11 |
| Website | https://www.humacyte.com |
As of April 18, 2026, 10:24 p.m. EDT: Options data reveals a heavily skewed put/call spread indicating defensive positioning. In short-term expirations (June 2026), put volume and Open Interest (OI) are dramatically higher than calls (190 vol/418 OI vs 190 vol/194 OI), suggesting significant buying of protection or bearish hedging near current levels ($0.71). For long-term expirations (Jan 2027+), in-the-money (ITM) puts accumulate substantial volume and OI (2,400+ OI at $1.5-$2.5 strikes), while far OTM calls show massive volume but high implied volatility (IV > 100% at some strikes), indicating a 'long wings' risk-on sprint to navigated asset at low cost. However, the fundamental data suggests these are likely non-directional NAV trading costs rather than genuine directional bets given the lack of earnings catalysts and massive cash burn. The lack of short-term call activity and the surge in put OI at low strikes point to a floor being established, not a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.51034486 |
| Address1 | 2,525 East North Carolina Highway 54 |
| All Time High | 17.45 |
| All Time Low | 0.547 |
| Ask | 0.7341 |
| Ask Size | 50 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 4,759,120 |
| Average Daily Volume3 Month | 6,920,672 |
| Average Volume | 6,920,672 |
| Average Volume10Days | 4,759,120 |
| Beta | 2.105 |
| Bid | 0.6882 |
| Bid Size | 50 |
| Board Risk | 5 |
| Book Value | 0.016 |
| City | Durham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7102 |
| Current Ratio | 3.69 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.7536 |
| Day Low | 0.7021 |
| Debt To Equity | 2,101.833 |
| Display Name | Humacyte |
| Earnings Call Timestamp End | 1,774,612,800 |
| Earnings Call Timestamp Start | 1,774,612,800 |
| Earnings Timestamp | 1,774,614,600 |
| Earnings Timestamp End | 1,778,589,000 |
| Earnings Timestamp Start | 1,778,589,000 |
| Ebitda | -100,092,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.724 |
| Enterprise To Revenue | 84.655 |
| Enterprise Value | 172,526,976 |
| Eps Current Year | -0.435 |
| Eps Forward | -0.18333 |
| Eps Trailing Twelve Months | -0.26 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.9365 |
| Fifty Day Average Change | -0.2263 |
| Fifty Day Average Change Percent | -0.24164441 |
| Fifty Two Week Change Percent | -51.034485 |
| Fifty Two Week High | 2.93 |
| Fifty Two Week High Change | -2.2198 |
| Fifty Two Week High Change Percent | -0.7576109 |
| Fifty Two Week Low | 0.547 |
| Fifty Two Week Low Change | 0.16320002 |
| Fifty Two Week Low Change Percent | 0.29835472 |
| Fifty Two Week Range | 0.547 - 2.93 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,606,833,000,000 |
| Float Shares | 190,860,946 |
| Forward Eps | -0.18333 |
| Forward P E | -3.8738887 |
| Free Cashflow | -71,891,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 184 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -76,366,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14151 |
| Held Percent Institutions | 0.25278 |
| Implied Shares Outstanding | 222,019,108 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina. |
| Long Name | Humacyte, Inc. |
| Market | us_market |
| Market Cap | 157,677,968 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_107706507 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -40,833,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 157,478,153 |
| Number Of Analyst Opinions | 7 |
| Open | 0.715 |
| Operating Cashflow | -105,042,000 |
| Operating Margins | -66.02998 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 919 313 9633 |
| Post Market Change | 0.019800007 |
| Post Market Change Percent | 2.7879481 |
| Post Market Price | 0.73 |
| Post Market Time | 1,776,470,003 |
| Previous Close | 0.6836 |
| Price Eps Current Year | -1.6326437 |
| Price Hint | 4 |
| Price To Book | 44.387497 |
| Price To Sales Trailing12 Months | 77.36897 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.773 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.57143 |
| Region | US |
| Regular Market Change | 0.0266 |
| Regular Market Change Percent | 3.89116 |
| Regular Market Day High | 0.7536 |
| Regular Market Day Low | 0.7021 |
| Regular Market Day Range | 0.7021 - 0.7536 |
| Regular Market Open | 0.715 |
| Regular Market Previous Close | 0.6836 |
| Regular Market Price | 0.7102 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 5,037,619 |
| Return On Assets | -0.52823 |
| Revenue Per Share | 0.013 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 222,019,108 |
| Shares Percent Shares Out | 0.1902 |
| Shares Short | 42,223,438 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 38,162,880 |
| Short Name | Humacyte, Inc. |
| Short Percent Of Float | 0.2094 |
| Short Ratio | 4.48 |
| Source Interval | 15 |
| State | NC |
| Symbol | HUMA |
| Target High Price | 25.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 5.10286 |
| Target Median Price | 1.5 |
| Total Cash | 50,497,000 |
| Total Cash Per Share | 0.227 |
| Total Debt | 65,346,000 |
| Total Revenue | 2,038,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.42508 |
| Two Hundred Day Average Change | -0.71487993 |
| Two Hundred Day Average Change Percent | -0.501642 |
| Type Disp | Equity |
| Volume | 5,037,619 |
| Website | https://www.humacyte.com |
| Zip | 27,713 |